Guardant Health, Inc.

Guardant Health Inc. is a precision oncology company that develops and provides blood and tissue-based tests, along with vast data sets and advanced analytics, to support cancer treatment, monitoring, and early detection. Its core offerings include the Guardant360 family of liquid biopsy tests, such as Guardant360 CDx for companion diagnostics, Guardant360 LDT measuring over 730 genes, Guardant360 Response for therapy monitoring, Guardant360 TissueNext with AI-powered PD-L1 detection, and GuardantINFINITY for comprehensive genomic profiling. The company also provides Guardant Reveal for minimal residual disease detection and the Shield blood test for colorectal cancer screening using genomic and epigenomic signals. Additionally, GuardantOMNI and GuardantINFORM platforms assist biopharmaceutical firms in clinical trials and real-world data analysis. Guardant Health Inc. serves oncologists, healthcare providers, and pharmaceutical partners in the United States and internationally, billing through insurance reimbursements and contracts. Founded in 2011 and headquartered in Palo Alto, California, it plays a pivotal role in advancing non-invasive cancer diagnostics and personalized medicine.